Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD) Who Have Had an Inadequate Response to Antidepressants Alone

Phase 3

Completed

Conditions: Major Depressive Disorder

Interventions: Drug: Placebo
Drug: Cariprazine

Registration Number: NCT03738215

Lead Sponsor: AbbVie

Brief Summary: The objective of this study is to evaluate the efficacy, safety and tolerability of cariprazine as an adjunctive treatment to antidepressant therapy (ADT) in patients with MDD who have had an inadequate response to antidepressants alone.

Detailed Description: Not available

Recruitment & Eligibility

Status: COMPLETED

Sex: All

Target Recruitment: 759

Inclusion Criteria

Written informed consent has been obtained.
Written documentation has been obtained in accordance with the relevant country and local privacy requirements, where applicable (eg, Written Authorization for Use and Release of Health and Research Study Information [US sites] and written Data Protection consent [EU sites]).
Patient must be an outpatient at the time of Visit 1 (Screening).
Patient meets the DSM-5 criteria for MDD based on SCID-5, with a current major depressive episode of at least 8 weeks and not exceeding 24 months in duration at Visit 1/Screening. A diagnosis of MDD with psychotic features will be acceptable.
Diagnosis of MDD confirmed through a formal adjudication process.
Patient demonstrates ability to follow study instructions and likely to complete all required visits.
Patient must have an inadequate response, as measured by the modified ATRQ, to 1 to 3 antidepressants administered during the current episode at an adequate dose (as per package insert) and for at least 6 weeks duration, with at least one dose escalation during the current depressive episode.
Only one antidepressant (of sufficient dose per package insert and taken for at least 6 weeks) will be allowed at randomization and patients must agree to continue taking the same ADT dosing regimen through completion of Visit 6/ET. Patients who are taking more than one antidepressant at Screening, regardless of the indication, will need to discontinue all other antidepressants prior to Visit 2 (Baseline).
Male and female patients must agree to use a medically acceptable and highly effective method of birth control during the course of the entire study.
Women of childbearing potential (only) must have a negative serum β-human chorionic gonadotropin pregnancy test prior to Visit 2.

Exclusion Criteria

Diagnosis of any current psychiatric diagnosis other than MDD (including those with current intellectual development disability) with the exception of specific phobias.
Patient has a history of intolerance or hypersensitivity to cariprazine or other drugs of the same class or to rescue medications.

Study & Design

Study Type: INTERVENTIONAL

Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Placebo + ADT	Placebo	During the double blind treatment period (6 weeks), participants will take 1 capsule of placebo, orally, per day in addition to their ongoing ADT (Same antidepressant and dose of ADT they were on at the Visit 2 baseline).
Cariprazine 1.5 mg/Day + ADT	Cariprazine	During the double blind treatment period (6 weeks), participants will take 1 capsule of cariprazine 1.5mg, orally, per day in addition to their ongoing ADT (Same antidepressant and dose of ADT they were on at the Visit 2 baseline).
Cariprazine 3 mg/Day + ADT	Cariprazine	During the double blind treatment period (6 weeks), participants will take 1 capsule of cariprazine 1.5mg, orally, per day for two weeks in addition to their ongoing ADT (Same antidepressant and dose of ADT they were on at the Visit 2 baseline). They will then titrate to Cariprazine 3 mg, orally per day, in addition to their ADT starting at Visit 4 (Week 2).

Primary Outcome Measures

Name	Time	Method
Total Score Change From Baseline to Week 6 in the MADRS (Montgomery-Åsberg Depression Rating Scale)	Baseline and Week 6	The MADRS is a 10-item, clinician-rated scale that evaluates the patient's depressive symptomatology during the past week. Patients are rated on items assessing feelings of sadness, lassitude, pessimism, inner tension, suicidality, reduced sleep or appetite, difficulty in concentration, and lack of interest. Each item is scored on a 7-point scale with a score of 0 reflecting no symptoms and a score of 6 reflecting symptoms of maximum severity. mITT Population included all randomized participants who had ≥1 postbaseline assessment of the MADRS total score. Number of subjects analyzed are the number of participants with data available for analyses.

Secondary Outcome Measures

Name	Time	Method
Change From Baseline to Week 6 in the Clinical Global Impressions-Severity (CGI-S) Score	Baseline and Week 6	The CGI-S is a clinician-rated scale used to rate the severity of the participant's current state of mental illness compared with MDD population. The participant was rated on a scale from 1 to 7, where 1=normal, not at all ill and 7=among the most extremely ill participants. Higher scores indicate worsening of mental illness. A negative change from Baseline indicates improvement. MMRM was used for analyses. mITT Population included all randomized participants who had ≥1 postbaseline assessment of the MADRS total score. Number of subjects analyzed are the number of participants with data available for analyses.

Trial Locations

Locations (125): Alea Research /ID# 234789
🇺🇸
Phoenix, Arizona, United States
Atria Clinical Research /ID# 237988
🇺🇸
Little Rock, Arkansas, United States
Woodland Research Northwest, LLC /ID# 236641
🇺🇸
Rogers, Arkansas, United States
California Pharmaceutical Research Institute /ID# 236732
🇺🇸
Anaheim, California, United States
Advanced Research Center /ID# 237957
🇺🇸
Anaheim, California, United States
Axiom Research /ID# 236268
🇺🇸
Colton, California, United States
ATP Clinical Research, Inc /ID# 236619
🇺🇸
Costa Mesa, California, United States
ProScience Research Group /ID# 236442
🇺🇸
Culver City, California, United States
Collaborative Neuroscience Research - Orange County /ID# 237639
🇺🇸
Garden Grove, California, United States
Irvine Clinical Research /ID# 237409
🇺🇸
Irvine, California, United States
Scroll for more (115 remaining)
Alea Research /ID# 234789
🇺🇸Phoenix, Arizona, United States